Global CAR T-Cell Therapy Market Set to Reach USD 29 Billion by 2029 | MarketsandMarkets™

Unprecedented growth at a CAGR of 39.6% positions CAR T-cell therapy as a transformative force in oncology

Delray Beach, FL, Aug. 26, 2025 (GLOBE NEWSWIRE) -- The global CAR T-cell Therapy market, valued at US$3.7 billion in 2023, stood at US$5.5 billion in 2024 and is projected to advance at a resilient CAGR of 39.6% from 2024 to 2029, culminating in a forecasted valuation of US$29.0 billion by the end of the period. This rapid acceleration underscores the convergence of critical factors: escalating cancer prevalence, robust funding pipelines, and significant technological advances in cell therapy.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47772841

Transforming Cancer Care: What Is Driving This Growth?
Cancer continues to represent one of the most pressing healthcare challenges worldwide. According to the World Health Organization, nearly 20 million new cancer cases and 9.7 million related deaths were reported in 2022, with projections estimating a 77% surge in cases by 2050. In this context, CAR T-cell therapy is emerging as a breakthrough solution, particularly in treating hematologic malignancies such as Diffuse Large B-Cell Lymphoma (DLBCL), which accounts for approximately 22% of B-cell non-Hodgkin lymphoma cases in the United States alone.

Why Now? Market Catalysts and Restraints
The rising cancer incidence and advances in genetic engineering technologies are propelling adoption of CAR T-cell therapies globally. However, accessibility remains a critical challenge. With treatment costs often surpassing USD 350,000 per patient, driven by complex manufacturing processes, affordability and scalability continue to restrict widespread adoption. At the same time, expansion into solid tumors represents an untapped opportunity for the next wave of therapeutic breakthroughs, unlocking broader applications and market potential.

Where Are the Opportunities Emerging?
Asia Pacific is forecasted to deliver the highest CAGR between 2024 and 2029, fueled by increasing healthcare investments, growing cancer incidence, and supportive regulatory frameworks. While North America remains the largest market today—thanks to early adoption, robust infrastructure, and strong regulatory pathways—emerging markets are expected to provide substantial long-term growth.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=47772841

Who Are the Market Leaders?
The CAR T-cell therapy landscape is consolidated, with key players including Bristol-Myers Squibb (US), Gilead Sciences (US), Novartis AG (Switzerland), Johnson & Johnson (US), CARsgen Therapeutics (China), IASO Biotherapeutics (China), JW Therapeutics (China), ImmunoAct (India), CRISPR Therapeutics (Switzerland), Autolus Therapeutics (UK), Allogene Therapeutics (US), Cartesian Therapeutics (US), Guangzhou Bio-gene Technology (China), and Wugen (US).

Notable recent developments highlight industry momentum:

• May 2024: The US FDA granted accelerated approval for Bristol Myers Squibb’s BREYANZI in relapsed/refractory Follicular Lymphoma.
• April 2024: Bristol entered a global supply partnership with Cellares to scale CAR T manufacturing using its automated Cell Shuttle platform.
• January 2023: Gilead Sciences secured FDA approval for a manufacturing upgrade to YESCARTA, reducing turnaround time from 16 to 14 days.

How Is the Market Shaping Strategically?
YESCARTA (Gilead Sciences) continues to dominate product share, supported by early entry, brand strength, and process innovations. CD19-targeted therapies remain the most commercially successful, reflecting their pivotal role in treating B-cell malignancies. Hospitals serve as the largest end-user base, while the adult patient demographic represents the leading consumer segment.
With expansion into solid tumors on the horizon and increasing automation in manufacturing, CAR T-cell therapies are positioned to shift from niche innovation to mainstream oncology treatment, redefining care models for cancer patients globally.

Company and Market Insights

• Gilead Sciences: Strengthened by acquisitions and strategic collaborations, including an expanded partnership with Arcellx in 2023, Gilead maintains a strong pipeline and competitive positioning.
• Bristol-Myers Squibb: With USD 9.3 billion invested in R&D in 2023, the company demonstrates unwavering commitment to oncology innovation.
• Novartis: A pioneer in CAR T-cell therapy with Kymriah—the first FDA-approved CAR T therapy—Novartis continues to leverage global reach and diversified distribution networks.

For more information, Inquire Now!

Discover Connected Healthcare Market Opportunities:
Cell Therapy Technologies Market
Gene Therapy Market
Gene Editing Market
Immunotherapy Drugs Market
Cancer Vaccines Market

Get access to the latest updates on Top Companies in CAR T-cell Therapy and CAR T-cell Therapy Market Size

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445,
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: www.marketsandmarkets.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.